Citations

Institution: Mayo Clinic Clear

Showing 10 of 108152 citations.

Outcomes By Refractory Status and Prior Therapies Received in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study
Bouabdallah, Krimo , Forward, Nicholas, Chen, Tsai-Yun, Camus, Vincent, Wang, Ming‐Chung , Carassou, Philippe, Chang, Hung , Offner, Fritz , Ghesquières, Hervé , Nowakowski, Grzegorz S. , Yasenchak, Christopher A. , Patterson, Monica, Ho, Linda , Rustia, Evelyn, Fanale, Michelle A. , Fenton, Keenan , Portell, Craig A. , Portell, Craig A , Hahn, Uwe, Bartlett, Nancy L. , Kim, Jeong‐Ah , Derenzini, Enrico

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 4489-4489

10.1182/blood-2024-200914 Get It

Introduction Patients (pts) with progressive disease after ≥2 prior lines of systemic therapy are unlikely to derive additional benefit from current salvage immunochemotherapies, and survival declines significantly with each subsequent treatment. Pts with refractory disease following second-line therapy have worse outcomes, with reported overall response rates (ORRs) of 1% to 14% and overall survival (OS) of 5 months (Blood. 2017;130[16]:1800-1808). While chimeric antigen receptor (CAR) T-cell therapy has become a preferred strategy in the second- and third-line settings, pts with R/R disease following CAR-T experience dismal survival, with progression-free survival (PFS) and OS as low as 3 and 5 months, respectively, and no agreed standard of care post CAR-T (Blood. 2022;140[24]:2527-2529). The randomized, global, phase 3 ECHELON-3 study (NCT04404283) was conducted in pts with R/R DLBCL after ≥2 prior therapies who were ineligible for hematopoietic stem cell transplant and/or CAR-T. Here, we present subgroup analyses in pts with 2 prior lines of therapy, refractory disease, or prior CAR-T. Methods In these subgroup analyses of ECHELON-3, eligible pts had 2 prior lines of systemic therapy, disease refractory to the last prior therapy, or prior exposure to CAR-T. Pts could qualify for ≥1 subgroup and were analyzed separately. Refractory disease was defined as stable or progressive disease as best overall response to last line of treatment or relapse ≤6 months from the end of treatment. Pts were randomized 1:1 to receive brentuximab vedotin (BV; 1.2 mg/kg) or placebo every 3 weeks (q3w), in combination with rituximab (R; 375 mg/m2) q3w and lenalidomide (Len; 20 mg) once daily. Efficacy was assessed by investigators per Lugano 2014 classification. The primary endpoint was OS, with key secondary endpoints of PFS and ORR. P values are descriptive. Results In total, 230 pts were enrolled in ECHELON-3 from April 2021 to November 2023, with a median follow-up of 16.4 months (range, 0.1-31.5 months). Overall, 94 pts with 2 prior lines of systemic therapy were enrolled and randomized to BV+Len+R (n=48) or placebo+Len+R (n=46). Median OS was 16.3 months (95% CI, 12.6 months-not estimable) with BV+Len+R vs 8.5 months (95% CI, 4.1-15.8 months) with placebo+Len+R (hazard ratio [HR], 0.557; 95% CI, 0.317-0.977; P=.0388). Median PFS was 7.1 months (95% CI, 3.6-12.6 months) with BV+Len+R vs 2.7 months (95% CI, 1.4-4.0 months) with placebo+Len+R (HR, 0.462; 95% CI, 0.279-0.764; P=.0020). ORR was 68.8% (95% CI, 53.7%-81.3%) with BV+Len+R vs 43.5% with placebo+Len+R (95% CI, 28.9%-58.9%; P=.0216); complete response (CR) rate was 52.1% vs 13.0%, respectively. Additional data for pts by lines of therapy received will be presented. In total, 194 pts with disease refractory to the most recent systemic therapy were enrolled and randomized to BV+Len+R (n=98) and placebo+Len+R (n=96). Median OS was 11.7 months (95% CI, 8.8-16.3 months) with BV+Len+R vs 5.5 months (95% CI, 3.7-8.5 months) with placebo+Len+R (HR, 0.566; 95% CI, 0.396-0.808; P=.0015). Median PFS was 4.1 months (95% CI, 2.8-5.4 months) with BV+Len+R vs 1.5 months (95% CI, 1.4-2.6 months) with placebo+Len+R (HR, 0.508; 95% CI, 0.363-0.712; P<.0001). ORR was 59.2% (95% CI, 48.8%-69.0%) with BV+Len+R vs 29.2% (95% CI, 20.3%-39.3%) with placebo+Len+R (P<.0001); CR rate was 34.7% vs 11.5%, respectively. Overall, 67 pts who received prior CAR-T were enrolled and randomized to BV+Len+R (n=32) and placebo+Len+R (n=35). Median OS was 15.6 months with BV+Len+R vs 4.4 months with placebo+Len+R (HR, 0.38; 95% CI, 0.2-0.75). Median PFS was 3.0 months with BV+Len+R vs 1.4 months with placebo+Len+R (HR, 0.41; 95% CI, 0.22-0.76). ORR was 65.6% (95% CI, 46.8%-81.4%) with BV+Len+R vs 25.7% (95% CI, 12.5%-43.3%) with placebo+Len+R (P=.0014); CR rate was 37.5% vs 11.4%, respectively. Conclusions BV+Len+R demonstrated a clinically meaningful improvement in all key efficacy outcomes, including CR and OS, in pts with 2 prior lines of therapy, disease refractory to prior treatment, or prior CAR-T. This treatment benefit was generally consistent with that observed in the overall ECHELON-3 study population. Therefore, BV+Len+R has the potential to address an unmet need for effective and tolerable therapy in heavily pretreated pts, as described above.
Presence of Circulating Tumor Cells on Peripheral Blood Flow Cytometry at Best Response Predicts Overall Survival in Multiple Myeloma
Bohra, Arwa , Zanwar, Saurabh , Olteanu, Horatiu , Otteson, Gregory E., Kumar, Shaji , Jevremović, Dragan , Gonsalves, Wilson I. , Horna, Pedro , Rajkumar, S. Vincent

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 3340-3340

10.1182/blood-2024-212089 Get It

Introduction: Myeloma response to treatment can be biochemical, pathological, or radiological, with pathological assessments being invasive. Next-generation blood flow (PBF) for assessment of circulating tumor plasma cells (CTCs) has shown promising results as a prognostic in Multiple Myeloma (MM) patients. CTC detection via PBF has a potential to serve as non-invasive method for assessing pathological burden of disease and response to treatment. Comparing CTC responses to the International Myeloma Working Group (IMWG) criteria will further help to understand PBF's utility in predicting response to therapy. Patients and Methods: The study conducted is a retrospective observational study. We included patients with MM treated at Mayo Clinic from 01/01/2011 to 12/31/2019 with CTC records available at the time of best response (BR) to frontline therapy. The CTC values were expressed as the number of plasma cell events per 150,000 Peripheral Blood Mononuclear Cells (CD38, CD138, CD19, CD45, Kappa, Lambda). The CTC levels were compared across all response(IMWG Criteria) groups at BR, and at baseline. The CTC response was expressed as % CTC decrease at BR from baseline. Time-to-event analyses utilized the Kaplan Meier method and Cox-proportional hazards models, with comparisons made using the log-rank test. Results: We identified 621 patients with CTC data at the time of BR to frontline therapy. Of these, 148 (24%) had baseline CTC data from diagnosis. The median age at diagnosis was 62.3 (27.2-83.7). The median follow-up was 66.15 months; the distribution of patients by treatment class is as follows- Alkylator: 0.8%, PI(Proteasome Inhibitor)+Cyclophosphamide: 27.4%, IMid: 12.7%, PI+IMid(Immunomodulator): 55.9%, PI+IMid+antiCD38: 3.2%; 378 patients (78.8%) underwent an autologous transplant. BR to initial therapy was sCR/stringent Complete Response (10, 1.6%), CR (230, 36.9%), VGPR/Very Good Partial Response (224, 36.1%), PR (123, 19.8%), MR/Minimal Response (12, 1.9%), SD/Stable Disease (14, 2.3%), PD/Progressive Disease (8, 1.3%). In the study, 64 patients (10.31%) had detectable CTCs at their BR. The distribution of CTCs across the different response categories was as follows: none (0%) in sCR, 3 patients (1.3%) in CR, 18 patients (8%) in VGPR, 24 patients (19.5%) in PR, 8 patients (66.7%) in MR, 6 patients (42.9%) in SD, and 5 patients (62.5%) in PD. The median CTC counts and their interquartile ranges for these categories showed significant variability: CR had a median of 46 (IQR: 28.5, 923), VGPR had 39.5 (IQR: 15.5, 111.25), PR had 47 (IQR: 22.75, 82.5), MR had 55 (IQR: 28.5, 85), SD had 96.5 (IQR: 22.25, 218.75), and PD had 317 (IQR: 57, 415). This Analysis of Variance (ANOVA) for response-wise distribution of CTC was <0.01. Response was dichotomized as PR and above for sCR, CR, VGPR, PR and less than PR for MR, SD and PD. Median Overall Survival(OS) for PR and above was 127.8 months (vs less than PR 56.7 months, p=0.01). Median OS for CTC+ at BR was 56.7 months (vs 134.8 for CTC negative, p=0.01). On multivariate analysis, presence of CTC at best response (Hazards Ratio = 2.9, n=1.1-2.9), RISS staging at diagnosis (Hazards Ratio = 2.35, n=1.5-3.05), less than PR (Hazards Ratio =1.8, 1.1-2.9) were independent predictors of inferior OS. In patients with data for CTC available at both baseline and at BR to frontline therapy (n=148), 110 had CTC detectable at diagnosis. Among patients in various response categories, a complete disappearance of CTCs was observed in sCR (n=3, 75.0%), CR (n=36, 69.2%), VGPR (n=38, 64.4%), and PR (n=14, 60.9%). CTC responses greater than 90% were noted in VGPR (n=3, 5.1%), PR (n=2, 8.7%), and SD (n=2, 40.0%). No CTC response was reported in sCR (1, 25.0%), CR (16, 30.8%), VGPR (2, 3.4% and 13, 22.0%), PR (3, 13.0% and both 2, 8.7%), SD (1, 20.0% and both 2, 40.0%), MR (1, 50.0%), and PD (1, 33.3% and 1, 50.0%, respectively). The median OS for those with a CTC response was 112.4 months vs 28.2 months for no response. (p=0.01). Conclusion: The presence of CTC at best response is an independent prognostic marker for inferior OS. Depth of response to frontline therapy correspond to a high rate of clearance of CTCs. Presence of CTC at best response provides independent prognostic value beyond the depth of response. A complete clearance of CTC at best response is associated with improved OS. CTC levels have not been corrected for WBC counts and may not be applicable in all settings.
Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab
Afrough, Aimaz , Dong, Wenli , Richards, Tiffany, Vazquez‐Martinez, Mariola , Sannareddy, Aishwarya , Goel, Utkarsh , Gaballa, Mahmoud , Rana, Masooma S, Ferreri, Christopher J. , Shune, Leyla , DeJarnette, Shaun, Ouchveridze, Evguenia, Forsberg, Peter A. , Hosoya, Hitomi , Mikkilineni, Lekha , Rossi, Adriana, Eberwein, Erin , Blue, Brandon , Sborov, Douglas W. , Voorhees, Peter M. , Patel, Krina K. , Sidana, Surbhi , Cowan, Andrew J. , Khouri, Jack , Davis, James A. , Sidana, Surbhi , Davis, James A , Hosoya, Hitomi , Pasvolsky, Oren , Feng, Lei , Davis, James A, Dima, Danai , Grajales‐Cruz, Ariel , Banerjee, Rahul , Lieberman-Cribbin, Alex , Julian, Kelley , Ouchveridze, Evguenia, Susanibar-Adaniya, Sandra P. , Portuguese, Andrew J. , Kaur, Gurbakhash , Rossi, Adriana , Herr, Megan M. , Lin, Chenyu , Raza, Shahzad , Lin, Yi , McGuirk, Joseph P. , Atrash, Shebli , Anwer, Faiz , Hansen, Doris K. , Anderson, Larry D. , Richard, Shambavi , Garfall, Alfred L. , Lee, Hans C.

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 3337-3337

10.1182/blood-2024-206357 Get It

Background: Teclistamab (Tec) received regulatory approval for the treatment of relapsed refractory multiple myeloma (RRMM) based on the MajesTEC-1 study. The risk of CRS and ICANS with Tec is well established with a manufacturer's recommendation of inpatient observation for 48-hours for CRS/ICANS monitoring after the initial 3 step up doses. There are limited real-world data on the characteristics of and risk factors for CRS and ICANS with Tec. Such data could inform management of Tec patients (pts), including patient selection for inpatient or outpatient step-up dosing. Methods: RRMM pts treated with standard-of-care Tec across 13 U.S. academic institutions were included in this analysis. The follow-up data cutoff was 30 April 2024. CRS and ICANS classification was based on the American Society for Transplantation and Cellular Therapy consensus grading criteria. Multivariable logistic regression models were fitted to estimate the effects of covariates on CRS and ICANS events, with a particular focus on grade ≥2 CRS, any-grade ICANS, and the combination of CRS grade ≥2 and/or any-grade ICANS. Results: 385 pts were included in the analysis, with a median of 6 lines of prior therapy. Median age was 68 years (range 31-92), 88 patients (25% of pts with available data) had ECOG ≥2, and 301 pts (78%) would have been ineligible for MajesTEC-1. 48 (33%) of 145 evaluable pts with a baseline bone marrow (BM) prior to Tec had >50% BM plasma cells, 139 pts (36%) had extramedullary disease (EMD) (either paraskeletal or true-EMD) and 5 pts (1%) had plasma cell leukemia prior to start of Tec. 224 pts (59%) received Tec with an accelerated step-up dosing regimen, defined as having at least one step-up dose interval of ≥ 2 days. 220 pts (57%) developed any-grade CRS [Grade 1: 46% (N=179), grade 2: 10% (N=37), grade 3: 0.8% (N=3), grade 4: 0.3% (N=1)]. Median time to CRS from start of Tec was 3 days (range, 0-15). Fifty-four pts (14%) developed any-grade ICANS [Grade 1: 7% (N=26), Grade 2: 5% (N=18), grade 3: 3% (N=10), grade 4: none]. There were no grade 5 CRS or ICANS events. Median time to onset of ICANS from start of Tec was 4 days (range, 0-25). There was one case of hemophagocytic lymphohistiocytosis in the entire cohort. 38% of pts received tocilizumab and 17% of pts received corticosteroids. In univariate analysis (UVA), baseline platelet <50, triple-class refractory, penta-refractory status, and EMD prior to start of Tec were associated with increased risk for CRS grade ≥2 (p-values <0.1) and incorporated in MVA. Baseline platelet <50, age >60, ECOG ≥2, Hgb <8 g/dL, BM plasma cells >50%, and ferritin or CRP in the upper quartile were associated with increased risk for any-grade ICANS in UVA (p-values <0.1). Baseline platelet <50, ECOG ≥2, Hgb <8 g/dL, BM plasma cells >50%, ferritin or CRP in the upper quartile, and prior BCMA exposure were associated with increased risk of CRS grade ≥2 and/or any-grade ICANS in UVA (p-values <0.1). Accelerated step-up dosing, renal impairment (CrCl < 30 mL/min) and baseline LDH in the upper quartile were not associated with an increased risk of either CRS or ICANS in UVA. Baseline BM plasma cells >50% was excluded from multivariable analysis (MVA) due to high number of missing data, since most pts (62%) did not undergo BM biopsy prior to start of Tec. In MVA, risk factors for CRS grade ≥2 included baseline platelet <50 at the start of Tec treatment (OR: 2.35, 95% CI 1.08-5.08; p=0.03) and penta-refractory disease (OR: 2.48, 95% CI 1.13-5.45; p=0.02). Risk factors for any-grade ICANS included platelet <50 (OR: 4.18, 95% CI 1.88-9.28; p=0.0004), age >60 (OR: 7.54, 95% CI 1.63-34.89; p=0.01) and CRP in the upper quartile (OR: 2.51, 95% CI 1.16-5.43; p=0.02). Risk factors for CRS grade ≥2 and/or any-grade ICANS included platelet <50 (OR: 2.65, 95% CI 1.42-4.94; p=0.002) and ECOG ≥2 (OR: 2.07, 95% CI 1.19-3.61; p=0.01). Conclusions: This real-world analysis of RRMM pts treated with Tec revealed comparable rates CRS and ICANS relative to the MajesTEC-1 study, and these were mostly limited to grade 1/2. MVA demonstrated a significantly higher risk of CRS grade ≥2 and/or any-grade ICANS in pts with baseline platelet <50 and/or ECOG ≥2, the former may reflect BM disease burden. These results may help identify pts who are at higher risk for IEC related toxicities with Tec that would warrant inpatient monitoring during initial step-up dosing. OP, AA, & LF: co-first authors. AG, HCL & JK: co-senior authors
Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome - a Multicenter Retrospective Analysis
Ball, Somedeb , Feld, Jonathan , Haddadin, Michael , Hawkins, Hayley, Guerra, Veronica , Dworkin, Emily , Tawfiq, Reema, Dulak, Dominika, Feng, Amber , Cotte, Christina , Cohen‐Nowak, Adam , Shukla, Asmita, Winer, Eric S. , Foucar, Charles , Shallis, Rory M. , Im, Annie , Szabo, Aniko, Murthy, Guru Subramanian Guru , Abboud, Ramzi , Patel, Shyam A. , Kishtagari, Ashwin , Balasubramanian, Suresh , Abaza, Yasmin , Lin, Chenyu , Badar, Talha , Patel, Anand , Atallah, Ehab

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 3206-3206

10.1182/blood-2024-211623 Get It

Background: Hypomethylating agents (HMA) with venetoclax (VEN) have shown encouraging clinical efficacy in single arm clinical trials for patients with myelodysplastic syndrome (MDS) (Garcia JS et al. ASH 2023, Zeidan AM et al. Am J Hematol. 2023). Many centers have started utilizing HMA-VEN in the clinical management of MDS due to unmet need, pending results of the ongoing phase 3 randomized clinical trial (VERONA) using this combination. However, real world studies with large sample size investigating the use of these agents in MDS, practice patterns and clinical outcomes are lacking. Methods: This is a multicenter retrospective study of 13 US academic medical centers. We included contemporary cohorts of adults (age≥18 years) with MDS who were treated with upfront combination of HMA-VEN, upfront HMA monotherapy, or VEN added after inadequate response or progression on HMA (post-HMA failure VEN). Outcomes analyzed includes clinical response, adverse events (AE) of interest, dose administration and survival. Descriptive statistics were used for baseline characteristics. Overall survival and event free survival (EFS: progression, leukemic transformation, death as events) analysis was conducted using Kaplan-Meier method. Determinants of outcomes were analyzed using multivariable regression models. All analyses were conducted at a significance level of p<0.05. Results: Among 454 patients included, 258 patients received VEN in combination with HMA [upfront HMA-VEN (n=175), post-HMA failure VEN (n=83)] and 196 patients received HMA monotherapy. Median age was 69 (59-77) years and majority of patients had MDS with excess blasts (75%), high risk (31.9%) or very-high (41.8%) risk disease by IPSS-R, 23.7% had therapy related disease, 33% had deletion17p or TP53 mutation and 40.9% underwent allogeneic stem cell transplantation. VEN was predominantly started in outpatient setting (78.6%) with tumor lysis syndrome (TLS) prophylaxis and VEN doses ranged from 70-400mg, adjusted for concomitant antifungal drugs. Incidence of TLS was minimal (No TLS- 92.9%, lab-only TLS 6.2%, 1 pt with clinical TLS). Neutropenic fever was the main AE noted [upfront VEN-HMA (34.2%), HMA monotherapy (22.5%), post-HMA VEN (44.5%)]. In the upfront setting, response rate was significantly higher with HMA-VEN than HMA monotherapy (CR: 33% vs 12%; marrow CR: 40% vs 27%, p<.001). VEN given in the post HMA failure setting also resulted in encouraging response rates (CR 10%, marrow CR 32%). After adjusting for covariates in multivariable analysis, patients treated with HMA-VEN in the upfront setting had significantly improved event free survival as compared to HMA monotherapy (HR 0.59, HR 0.44-0.78, p<0.01), but overall survival did not reach statistical significance (overall survival HR 0.77, 95%CI 0.57-1.04, p=0.08). Conclusions: In this large multicenter retrospective analysis from US academic medical centers, we found that VEN in combination with HMA resulted in encouraging clinical outcomes and was effectively administered in the outpatient setting with minimal TLS. Infection risk management and supportive measures would be important to improve the ability to use this treatment widely, pending results of the ongoing phase 3 randomized clinical trial. Updated results with additional variables will be available at the main meeting.
Updated Efficacy and Safety Results of Patients Receiving Selected 100mg Bezuclastinib Dose and Participating in the Open-Label Extension of Summit: A Randomized, Double-Blind, Placebo Controlled Phase 2 Clinical Trial of Bezuclastinib in Adult Patients wi
Rein, Lindsay , Cridtina, Bulai Livideanu, Üstün, Celalettin , Boggs, Nathan, Kirshenbaum, Arnold S. , Dybedal, Ingunn , Yi, Cecilia Y. Arana , Herrscher, Richard, Patel, Jay , Sun, Lei, Shah, Nisha , Zhang, Jenna, Pilla, Amanda, DeAngelo, Daniel J. , Modena, Brian D. , Oh, Stephen T. , Boggs, Nathan, Manning, Michael, Hunter, Anthony M. , Akin, Cem , Yi, Cecilia Arana , Castells, Mariana , Lansigan, Frederick , George, Tracy I. , Shah, Nisha, Singh, Priya , Carden, Marcus A. , Siebenhaar, Frank , Bose, Prithviraj

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 4556-4556

10.1182/blood-2024-194551 Get It

Background: Systemic mastocytosis (SM) is a rare disease characterized by neoplastic mast cell (MC) infiltration of extracutaneous tissues. Nonadvanced SM (NonAdvSM) is associated with debilitating symptoms which may significantly reduce health-related quality of life (HRQoL). In up to 95% of patients (pts), SM is driven by the somatic KIT c.2447 A>T (p.D816V) missense mutation. Bezuclastinib (bezu; CGT9486) is an oral, potent, small molecule, selective type 1 tyrosine kinase inhibitor (TKI) with activity against KIT D816V. Results from Part 1 of the 3-part Summit trial demonstrated that bezu is well-tolerated and is associated with encouraging clinical activity, including both reduced MC burden and improvement in symptoms over a 12-week (wk) period vs placebo (PBO). Based on safety, PK, biomarker, and efficacy results, a dose of 100mg QD bezu (optimized formulation) was selected for Summit Part 2. Trial Design and Methods: Summit (NCT05186753) is a multi-center, Phase 2, double-blind, PBO-controlled RCT of bezu in pts with NonAdvSM who have inadequate control of symptoms despite treatment with best supportive care (BSC). A novel pt-reported outcome measure, the Mastocytosis Symptom Severity Daily Diary (MS2D2), was designed to assess disease-specific symptom severity in NonAdvSM pts. Eleven symptoms are included in the MS2D2 Total Symptom Score (TSS). Summit Part 1a randomized pts 1:1:1 to PBO, 100mg, or 200mg, original formulation while Part 1b randomized 1:1:1 to PBO, 100mg, or 150mg, optimized formulation. Pts completing Part 1 of the Summit trial were allowed to receive bezu in the open-label extension (OLE) Part 3 of the trial. Results: As Part 2 will evaluate safety and efficacy of 100 mg bezu at 24 wks, this abstract reports on pts treated with both bezu formulations at 100mg in Parts 1a or 1b, which had similar PK exposures. The presentation will focus on 24-wk outcomes in pts receiving the selected 100 mg bezu dose and participating in the OLE. In Summit Part 1, 19 pts received PBO and 18 received 100 mg bezu for 12 wks. At baseline (BL), the symptoms identified as most severe were within the skin and fatigue domains. At BL, pts were managing their symptoms of NonAdvSM with 2 (43%), 3 (24%), or ≥4 (32%) BSC medications. At the 12-wk assessment in Part 1 (datacut 18Dec2023), the safety and tolerability profile was encouraging, with the majority of TEAEs low grade and reversible without dose modification. The most common TEAEs (>10% in 100 mg bezu) included hair color changes, nausea, diarrhea, peripheral edema, GERD, taste disorder, and neutropenia. There were no reported bleeding or cognitive impairment events. Of 37 pts randomized to PBO or 100 mg QD bezu, 36 (97%) received bezu in the OLE; one pt randomized to the 100 mg original formulation dose reduced and subsequently discontinued due to TEAE of ALT increase. All 19 PBO pts (100%) crossed over to receive bezu in the OLE; of these, 9 were randomized to the 100mg QD bezu dose. Reduction in MC burden was robust among those treated with 100mg bezu - 94.4%, 100%, and 92.3% of pts had at least a 50% reduction in basal serum tryptase, KIT p.D816V variant allele frequency, and bone marrow MCs, respectively. Pts treated with 100 mg bezu had reduction in MS2D2 TSS by 49.1% vs 21.1% with PBO. On a 0-10 scale, the most severe MS2D2 symptom mean change from BL was -3.03 from a BL mean of 7.6 with bezu vs -1.04 from a BL mean of 7.7 with PBO. Individual symptoms of the MS2D2 TSS, as well as others not in the TSS including diarrhea and brain fog, improved more with bezu than with PBO; mean change from BL ranged from -1.66 to -2.69 with bezu vs. a range of -0.52 to -1.58 with PBO. LS mean change from BL in quality of life (Mastocytosis (MC)-QoL, a disease-specific measure) was -22.05 in pts treated with 100mg bezu versus -10.71 in pts treated with PBO. Objective measurements of skin lesions, including centrally adjudicated longitudinal assessments of skin photography, also significantly reduced on bezu. Conclusions: In Part 1 (12 wk assessment), treatment with 100mg bezu resulted in favorable safety and tolerability, significant and deep reductions across all markers of MC burden, and clinically meaningful reduction in all individual MS2D2 TSS symptoms and across domains. The presentation will report on durability and safety/tolerability data beyond 12 wks for those pts randomized to 100 mg in Part 1 and pts who crossed over from PBO in Part 1 to 100mg in Part 3. Summit Part 2 is actively enrolling.
Final Results from the Phase 2 Revive Study Investigating the Hepcidin Mimetic Rusfertide in Patients with Polycythemia Vera (PV)
Kremyanskaya, Marina , Ritchie, Ellen K. , Palmer, Jeanne , Pettit, Kristen , Priego, Victor, Yacoub, Abdulraheem , Gupta, Suneel , Khanna, Sarita, Molina, Arturo , Pemmaraju, Naveen , Pettit, Kristen , Gerds, Aaron T. , Kuykendall, Andrew , Gotlib, Jason , Nath, Uttam Kumar , Bandyopadhyay, Arkapal

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 4559-4559

10.1182/blood-2024-197985 Get It

Background: PV is a myeloproliferative neoplasm that leads to excessive production of erythrocytes and increased platelet and leukocyte counts. The current standard of care is to use therapeutic phlebotomy (TP) with or without cytoreductive therapy (CRT) to treat PV. Over time, the CRT dose often needs to be increased to treat PV progression. Preliminary results from the phase 2 REVIVE study (NCT04057040) demonstrated that rusfertide was superior to placebo in achieving hematocrit (Hct) levels <45% and reducing or eliminating the need for TP in patients who were phlebotomy-dependent prior to study entry (Kremyanskaya et al. EHA2023. [Abstract LB2710]; Kremyanskaya et al. New Engl J Med 2024;390:723-35).Final data from REVIVE will be presented. Methods: In Part 1 (Weeks 1-29), subcutaneous rusfertide (starting dose: 20 mg q1w) was initiated and titrated to control Hct to <45%. In Part 2 (Weeks 29-41; blinded randomized withdrawal phase), patients were randomized to receive rusfertide or placebo. Randomized patients were eligible to participate in the open-label extension (OLE) portion of the study (Part 3), in which all patients could receive rusfertide and investigators could make CRT dose adjustments. Results: In Part 1, 70 patients were enrolled; 59 were randomized in Part 2. Fifty-eight patients continued to Part 3. As of 9 July 2024, 50 (71.4%), 37 (52.9%), and 17 (24.3%) patients received rusfertide for ≥2, ≥2.5, or ≥3 years, respectively.Overall, median (range) patient age was 57.5 years (27-77); the majority were male (70%) and had high-risk disease (55.7%). Overall, 52.9% and 47.1% of patients were treated with TP alone or TP plus CRT, respectively. Prior to enrollment, the estimated average (mean) phlebotomy rate (EAPR) in patients who enrolled on study was 8.5/year, which was reduced to <1.0/year in Part 1. In Part 2, the EAPR was <1.0/year and 6.6/year in the rusfertide and placebo groups, respectively. For patients who continued onto Part 3 and received rusfertide, the EAPR remained at <1.0/year. In Parts 1, 2, and 3, the mean (SD) weekly average rusfertide dose was 30.7 mg (12.2), 38.5 mg (21.3), and 44.9 mg (20.3), respectively. Rusfertide consistently maintained Hct <45%, including in patients receiving therapy for ≥3 years. Platelets increased following initiation of rusfertide therapy and stabilized over time; mean leukocyte counts remained stable. Prior to enrollment, iron-related parameters were consistent with systemic iron deficiency. Throughout the study, rusfertide resulted in the normalization of mean serum ferritin levels, increased mean transferrin saturation, and increased mean serum iron levels. Overall, mean corpuscular volume increased slightly over the duration of the study. Throughout the study, there was no evidence of increased markers of inflammation (eg, C-reactive protein or interleukin 6). The most common (≥20%) treatment-emergent adverse events (TEAEs) were injection site reactions (85.7%), fatigue (38.6%), COVID-19 (32.9%), pruritus (34.3%), arthralgia (30.0%), dizziness (30.0%), nausea (24.3%), headache (24.3%), and anemia (21.4%). Grade 3 TEAEs occurred in 25.7% of patients.There were no Grade 4 or 5 TEAEs. One patient developed acute myeloid leukemia after treatment discontinuation. After more than 150 patient-years of rusfertide exposure, malignancies (most of which were skin cancers) were reported in 11 patients (all had risk factors that may have contributed to the development of these malignancies). There was no obvious correlation between increasing exposure to rusfertide and malignancies reported. Six thrombotic events (5 arterial and 1 venous) occurred in 5 patients with high-risk PV. Conclusions: In REVIVE, rusfertide added to TP with or without CRT provided long-term durable control of Hct and decreased the need for TP. Patients are eligible to roll over to the phase 2 THRIVE OLE study (NCT06033586), which will continue to assess the long-term safety and efficacy of rusfertide for a total period of up to 5.8 years. The randomized phase 3 VERIFY study (NCT05210790) is ongoing and will evaluate rusfertide vs placebo in PV patients.
A Multi-Center Retrospective Study on Complex Karyotype in Patients with Richter Transformation Who Received No Chemoimmunotherapy for Their CLL
Allan, John N. , Brander, Danielle M. , Byrd, John C. , Danilov, Alexey V. , Dvorak‐Kornaus, Kaitlyn, Hampel, Paul J. , Islam, Prioty , Malakhov, Nikita , Miller, Sarah , Rogers, Kerry A. , Skarbnik, Alan P , Scott, Hamish W , Schade, Jake , Woyach, Jennifer A. , Kittai, Adam S. , Byrd, John C. , Byrd, John C , Miller, Cecelia , Huang, Ying , Bhat, Seema A. , Bond, David A. , Chavez, Julio C , Chong, Elise A. , Dowling, Mark R. , Ho, Carrie , Matasar, Matthew J. , Parikh, Sameer A. , Rabe, Kari G. , Rhodes, Joanna , Roeker, Lindsey E. , Saha, Aditi , Shadman, Mazyar , Shouse, Geoffrey , Stephens, Deborah M. , Thompson, Meghan C , Thompson, Philip A , Wang, Yucai , Yano, Max , Omer, Zulfa

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 3245-3245

10.1182/blood-2024-205668 Get It

Introduction: Complex karyotype (CK, ≥3 chromosome (chr) abnormalities (abn)) is an important adverse prognostic indicator in chronic lymphocytic leukemia (CLL). CK at diagnosis (dx) of CLL, particularly with major structural chr abn (i.e. unbalanced translocation, add, marker, ring chr), called type-2 CK (CK2), has been associated with an increased risk of Richter transformation (RT) (Visentin Haematologica 2022). RT is defined as development of aggressive lymphoma, most often large B-cell lymphoma, in the setting of CLL. In patients (pts) with relapsed/refractory CLL treated with ibrutinib, CK as a continuous variable and the presence of polyploidy were independent predictors for RT. CK is a common finding at the time of RT, and high-CK (≥5) has been associated with short survival in RT, although previous studies predominantly included pts with prior chemoimmunotherapy (CIT) administration for their CLL. The prognostic significance of CK in pts with RT whose prior CLL-directed therapies include only non-CIT, as is the current standard of care for CLL, has not been evaluated. Methods: We conducted a multicenter, retrospective analysis of pts from 14 academic centers. Pts with RT diagnosed between 6/2011 to 6/2023, who had CLL-directed treatment that did not include prior CIT, with stimulated karyotype data available, were included. Pts who did not receive treatment for their CLL prior to developing RT were not included. Baseline pt, disease, and cytogenetics data were collected via chart review at time of CLL diagnosis and at the development of RT. Karyotype abn up to 20 were counted on both CLL tissue (peripheral blood or bone marrow) and RT tissue using IWGMC guidelines (Chun Leuk Res 2010). CK was categorized as CK1 (balanced abn, deletion, aneusomies) or CK2. Polyploidy was defined as ≥58 chrs. Karyotype was considered evolved if one or more chr abn were seen in a follow-up sample of CLL tissue that were not seen at CLL dx.TP53 disruption was defined as presence of del(17p) or TP53 mutation. Overall survival (OS) was measured from RT dx and estimated using the Kaplan-Meier method. Cox regression model was used to identify prognostic factors associated with OS. Results: A total of 64 eligible pts were identified. Median age at RT dx was 65 years (range 40-89) and 71.9% of pts were male. Of those evaluated (n=49), 79.6% had unmutated IGVH. Median number of therapies for CLL prior to RT was 1 (range 1-5) and included BTK inhibitor (n=37), BCL2 inhibitor (n=3), both (n=18), or other non-CIT treatment (n=6). At CLL diagnosis, 54.7% of pts had a CK, and the median number of chr abn was 3 (range 0-20). Of those with CK, 96.9% had a CK2, and 6.3% had a polyploid subclone. TP53 disruption was found in 46% of pts. At time of RT, chr analysis of CLL tissue was available for 38 pts and showed 78.9% had a CK, and the median number of chr abn was 8 (range 0-20). Polyploidy was found in 29.6%. TP53 disruption (46 pts evaluated) was found in 52.2%. Karyotype evolution from dx (35 pts evaluated) occurred in 74.3% of pts. In RT tissue, of those evaluated (n=29), 96.6% were clonally related to the preceding CLL. MYC translocation (45 pts evaluated) occurred in 17.8%. CK (20 pts evaluated) was found in 70%, with a median number of chr abn of 8 (range 0-20). Of those with CK, 33.3% had a polyploid subclone. With a median follow-up of 17.8 months (range 2.1-83.0) there were 42 deaths, with a median OS of 14.3 months (range 6.9-29.1). For this subset of patients with karyotype data available who would go on to develop RT, an exploratory univariable analysis for OS from RT found that increasing number of chr abn as a continuous variable at CLL dx was associated with worse OS (HR 1.10, 95% CI 1.02-1.19, p=0.01). Similarly, at RT, increasing number of chr abn in CLL tissue (HR 1.09, 95% CI 1.02-1.16, p=0.01) and in RT tissue (HR 1.09, 95% CI 1.01-1.18, p=0.03) was also prognostic of survival. Karyotype evolution in CLL tissue at RT (HR 3.02, 95% CI 1.02-8.94, p=0.05) was borderline significant for worse OS. Conclusions: Our multi-center study identified increasing number of chr abn at CLL diagnosis and at time of RT, and clonal evolution in the CLL tissue, are associated with worse OS in pts with RT whose CLL was treated without CIT. Limitations include incomplete cytogenetics data across the cohort and potential variability across institutions in cytogenetics laboratory practices. This provides further evidence for the clinical utility of chr analysis in the modern era of CLL therapy.
Distinguishing between Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma with FTIR/ML of Serum
Khonkhammy, Darlyna, Gunnarson, Caden , Morena, Zach, Que, Dan, Dingli, David , Khammanivong, Ali

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 3295-3295

10.1182/blood-2024-194730 Get It

Monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and active multiple myeloma (MM) represent a continuum across the spectrum of plasma cell disorders. While patients with MGUS can be observed, it has a risk of progression to MM, while patients with SMM have a higher risk of progression to MM. Determining the risk of progression is important for proper patient care and elimination of anxiety, especially for patients identified at very low risk of progression. In contrast, identifying patients at high risk may reduce morbidity by more active surveillance or the introduction of therapy. We hypothesized that Fourier Transform InfraRed Spectroscopic analysis of serum combined with machine learning (FTIR/ML) could be used to facilitate this decision-making and correctly stratify patients' risk. Methods: After Institutional Review Board approval, we identified 99 patients with MGUS who did not progress to SMM/MM or AL amyloidosis, 96 patients with SMM who did not progress to active MM over a 2-year interval from diagnosis, and another 96 SMM patients who progressed to MM within two years of diagnosis. The patients had been diagnosed and followed up at Mayo Clinic in Rochester. Serological molecular fingerprint analysis was then performed using surface- and chemical-enhanced infrared absorption FTIR spectroscopy combined with artificial neural network ML. A randomized 10-fold cross-validation analysis was performed using 262 samples for training and the remaining 29 samples for validation to assess the model across ten independent iterations. Receiver operator characteristic (ROC) analysis was used to assess the FTIR/ML algorithm output compared to the clinical outcome data. Results: The patients with both MGUS and SMM had a similar median age (64.4 years), but patients with SMM tended to have lower hemoglobin compared to MGUS (median 12.4 versus 13.8g/dl respectively). As expected, patients with SMM also had a higher serum M-spike (2.0g/dl versus 1.2) and a higher clonal plasma cell burden in the bone marrow (20% versus 9%). FTIR/ML was able to correctly classify sera into MGUS in 95.8% of samples and SMM in 92.9% of samples. This gave an average accuracy of 94.8%. We performed ROC analysis and determined an area under the curve of 98.7%. The F1 score/precision was 94.9%, with a recall of 94.8%. After establishing a suitable threshold, the ML algorithm was able to correctly classify MGUS in 96.8% and SMM in 97.2% of cases. Conclusion: A single serum test at the time of diagnosis can correctly distinguish between MGUS that will not progress to another plasma cell disorder from smoldering multiple myeloma with a high degree of accuracy. Given that the patients with MGUS that were chosen had not progressed to a plasma cell disorder and were correctly identified, this methodology offers an opportunity to provide reassurance and minimize the need for repeat testing and follow-up of such patients.
Diagnosis of AL Amyloidosis Versus Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma Using FTIR/ML Analysis of Serum
Khonkhammy, Darlyna, Gunnarson, Caden , Morena, Zach, Que, Dan, Dingli, David , Khammanivong, Ali

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 3296-3296

10.1182/blood-2024-194736 Get It

The prognosis of patients with immunoglobulin light or heavy chain amyloidosis (AL/AH) has improved with the advent of more effective therapies. However, diagnosis is often delayed, with a negative impact on overall survival due to irreversible end-organ damage. Therefore, technologies that could facilitate the diagnosis or raise early suspicion of AL/AH amyloidosis in patients would be beneficial to improve outcomes. We hypothesized that Fourier transform infrared spectroscopic analysis of serum combined with machine learning (FTIR/ML) may be able to correctly diagnose AL/AH amyloidosis compared to patients with monoclonal gammopathy of undetermined significance or smoldering multiple myeloma. Methods: After institutional Review Board approval, we identified 90 patients with AL/AH amyloidosis, 99 patients with MGUS, and 192 patients with smoldering multiple myeloma (96 each who did/did not progress to active myeloma within two years of diagnosis) that had been diagnosed and followed up at Mayo Clinic in Rochester. We then performed surface- and chemical-enhanced infrared absorption FTIR/ML-based molecular fingerprint analysis on serum samples taken from the time of diagnosis to train an AI algorithm to distinguish between the two cohorts. A randomized 10-fold cross-validation analysis was performed using 253 samples (90% from each group) for training and the remaining 29 for testing to assess the model across ten independent iterations. We performed a Receiver Operator Characteristic analysis of the outcomes to measure the model's performance. Results: The patients with immunoglobulin-related amyloidosis had involvement of one or more of the following organs: heart, kidneys, liver, nerve, and gastrointestinal tract. Patients diagnosed with amyloidosis had lower serum albumin (3.0 versus 3.6 g/dl) and higher lambda immunoglobulin-free light chain values compared to those with MGUS (28.4 versus 1.92mg/dl). The predominance of lambda immunoglobulin-free light chains is not unexpected but not diagnostic by itself of AL/AH amyloidosis. Patients with SMM had higher serum M protein, higher immunoglobulin kappa free light chains, and higher bone marrow plasma cell burden (20%) compared to either MGUS (9%) or AL amyloidosis patients (10%). However, none of these are diagnostic features. FTIR/ML was able to correctly classify AL/AH amyloidosis in 80% of samples and MGUS in 83.8%, for an accuracy of 82% with an area under the curve of 89.2%. The precision was 82%, with a recall of 82%. After setting an appropriate threshold, the algorithm was able to correctly identify AL/AH amyloidosis in 86.1% of patients and MGUS in 86.6% of patients. When we compared AL/AH amyloidosis with SMM, FTIR/ML correctly classified AL/AH amyloidosis in 94.4% and SMM in 96.4% for an accuracy of 95.7% and an area under curve of 97.5%. The precision was 95.8%, with a recall of 95.7%. After setting a threshold, the algorithm was able to correctly diagnose SMM in 98.3% and AL/AH amyloidosis in 96.2%. Discussion: FTIR/ML analysis of serum can distinguish between AL/AH amyloidosis and both MGUS and SMM with a high degree of accuracy. Given that the diagnosis of immunoglobulin related amyloidosis is often delayed, our approach, based on a single analysis of a serum sample could potentially accelerate the diagnosis of AL/AH amyloidosis and implementation of life saving therapy.
Isatuximab in Relapsed AL Amyloidosis: Results of a Prospective Phase II Trial (SWOG S1702)
Parker, Terri L., Landau, Heather , Kapoor, Prashant , Girnius, Saulius, Hagen, Patrick , Scott, Emma C. , Hoering, Antje , Durie, Brian G.M. , Rosenthal, Adam , Sanchorawala, Vaishali , Campagnaro, Erica , Neparidze, Natalia , Orlowski, Robert Z.

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 3378-3378

10.1182/blood-2024-208341 Get It

Background: Isatuximab is an IgG1κ monoclonal antibody that binds with high affinity to CD38 expressed on plasma cells in light chain (AL) amyloidosis. Anti-CD38 antibodies have shown efficacy alone and in combination in a variety of settings for patients with multiple myeloma and light chain (AL) amyloidosis. Here we report the final analysis of a multi-center, cooperative group prospective phase II study of isatuximab in previously treated patients with AL amyloidosis (NCT03499808). Methods: Eligibility included: age ≥18 years, relapsed or refractory systemic AL amyloidosis, ≥1 prior line of therapy, measurable disease, ≥1 organ involved, not refractory to daratumumab, Eastern Cooperative Oncology Group performance status ≤2, creatinine clearance ≥25 mL/min, and NT-proBNP ≤8500 pg/mL. Patients received isatuximab intravenously 20 mg/kg weekly during the first 28-day cycle and every other week during cycles 2 through 24 for a maximum of 24 cycles. The primary objective was hematologic response with secondary objectives of organ response, safety, progression free survival, and overall survival. Results: Forty-three patients were registered, with 35 patients being eligible for response. The median age of the evaluable patients was 70 years (range, 40.1-79.5) with the majority (66%, n=23) having a lambda clonal plasma cell dyscrasia. The most common cytogenetic abnormality using fluorescence in situ hybridization was translocation t(11;14) observed in ten patients (29%). The most common prior treatment was a proteasome inhibitor (94%, n=33) while 46% (n=16) had undergone autologous stem cell transplant. Eighteen patients (51%) had single organ involvement while 17 (49%) had multiple organs involved. The distribution of organ involvement was typical for AL amyloidosis with cardiac involvement in 25 patients (71%) and renal involvement in 14 (40%). As of December 30, 2022, no new safety concerns were identified. The most common treatment related grade ≥3 adverse events included lymphopenia (n=3, 8.5%) and infection (n=2, 6%). The overall hematologic response rate was 77.1% with a rapid median time to partial response or better of 1.1 months. Two patients (6%) achieved a hematological complete response (CR), 18 (51%) had a very good partial response (VGPR), and 7 (20%) had a partial response (PR). At 24 months from hematologic response, the rate of patients still in response was estimated at 81% (95% confidence interval (CI): 67, 96). The 24-month estimated overall survival was 85% (95% CI: 73%, 97%). Renal response occurred in 50% (7/14) of patients with renal involvement with a median time to response of 18.5 months. Cardiac response occurred in 56% (14/25) of patients with cardiac involvement with a median time to response of 16.6 months. Conclusions: Isatuximab monotherapy resulted in high rates of hematologic response in relapsed AL amyloidosis which translated into organ responses. Treatment appears safe and was well tolerated. Support: NIH/NCI/NCTN grant awards U10CA180888, U10CA180819, CA180820, and CA180821; and in part by Sanofi-Aventis (Sanofi US)